Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 16, 2007

Altair Therapeutics Formed to Exploit Isis IP

  • Altair Therapeutics has been created on the basis of Isis Pharmaceuticals antisense IP. Isis will own 18% of Altair, which will focus on respiratory conditions.

    Under this transaction, Altair gains the exclusive, worldwide license for the development and commercialization of ISIS 369645. The compound is an inhaled inhibitor of the IL-4/IL-13 signaling pathways.

    The companies will also collaborate to discover drugs directed to other targets. Altair will pay Isis development milestones and royalties related to ISIS 369645 and other drugs arising out of the partnership.

    “Altair is assembling a focused team of experts in both antisense drug discovery and development and respiratory conditions to advance antisense drugs including ISIS 369645,” according to Jeff Jonas, M.D., evp of Isis.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.